Background

Lymphomas are a diverse group of clonal neoplasms arising from B and T lymphocytes and natural killer cells. Manipulation and silencing of the host’s immune system by methods ranging from changes in the cellular microenvironment composition to changes in distinct signalling pathways is an important feature of various lymphomas [1, 2]. Chemotherapeutic treatment of these diseases can also cause prolonged and profound neutropenia and immunosuppression. Therefore, individuals with lymphoma are at high risk for developing opportunistic infections. The incidence of tuberculosis (TB) has been reported to range from 0.9 to 13.2%, and that of miliary TB has been reported to be 35 times higher than in the general population [3, 4]. A retrospective study revealed that the incidence of invasive fungal infection (IFI) was 1.1% in Hodgkin’s lymphoma (HL) patients and 0.3% in non-Hodgkin’s lymphoma (NHL) patients [5]. Aspergillus was the most frequent causative pathogen, and most cases appeared during intensive therapy for tumours using chemotherapy, immunosuppressive agents or haematopoietic stem cell transplantation [5, 6]. However, a rare clinical scenario remains in which lymphoma and opportunistic infection exist simultaneously at presentation. The exact incidence is unknown, and it is often confined to single cases. The presence of one disease may eclipse another and thereby provide a challenge to clinicians. Here, we present the case of a patient with synchronous pulmonary aspergillosis and diffuse large B-cell lymphoma at presentation to improve our understanding of this condition.

Case presentation

A 48-year-old male was referred to the clinic for recurrent fever, cough and 5-kg weight loss during past 3 months. He denied breathing difficulties, chest pain, night sweats, wheezing and other uncomfortable symptoms. He was a smoker of 30 pack-years and had no history of travel or TB. There were no significant findings in his prior medical or family history.

At the time of the initial evaluation, the patient showed an auricular temperature of 39.2 °C, a blood pressure of 108/70 mmHg, a pulse of 108, and a respiratory rate of 20. He had diminished breath sounds on both sides, and no enlarged lymph nodes were noted. Examinations of the heart, abdomen, extremities and nervous system were normal.

Laboratory data showed that the patient’s white blood cell count, haemoglobin level and platelet count were normal. C-reactive protein and lactate dehydrogenase (LDH) levels were elevated at 151.00 mg/L (normal range: 0~8 mg/L) and 395.00 U/L (0~247 U/L). Tumour markers, such as CEA, NSE, SCCA, ProGRP and CYFRA21-1, were all in the normal range. HIV serology was also negative. Computed tomography (CT) of the chest showed bilateral cavitating lesions with mediastinal enlarged lymph nodes (Fig. 1, A-C). The patient was started on empiric antibiotic treatment with cefoperazone-sulbactam. After 3 days of therapy, his temperature was still above 38.5 °C. A CT-guided biopsy of the pulmonary cavity was performed on the 4th day after admission. Pathology revealed mild atypical alveolar epithelioid cells and chronic interstitial fibrous tissue proliferation with necrosis. The tissue was negative on smear and culture for acid-fast bacilli. Periodic Acid-Schiff (PAS) stain was also negative. The patient’s antibiotics were changed to imipenem-cilastin sodium and metronidazole. However, the second combination of antibiotics was ineffective. The patient was still febrile, and further blood cultures remained negative. On the fifth day, he underwent bronchoscopy and bronchoalveolar lavage, which were negative for any masses, abscesses or areas of bleeding. However, the patient tested positive for galactomannan antigenemia in bronchoalveolar lavage fluid (BALF) and blood. Aspergillus fumigatus complex was identified from the BALF culture on the 10th day. Due to the new microbiological findings, the patient was treated with voriconazole. In addition, the patient was still treated with linezolid, moxifloxacin and imipenem-cilastin sodium combined with metronidazole successively during the third round of antibiotic use. He was persistently febrile and developed breathing difficulties. We recommended the patient undergo positron emission tomography/computed tomography (PET-CT) to assess the possibility of haematological malignancies. It was refused because of the financial burden. We performed bone marrow aspiration on the 20th day. No abnormal cells were observed in the bone marrow examination. A CT scan performed 23rd day revealed further expanding consolidation and bilateral pleural effusion (Fig. 1, D-F). Thoracentesis was performed on the 24th day. Pleural fluid analysis revealed a red blood cell count of 16,320 cells/μL and a nucleated cell count of 1280 cells/μL (31% lymphocytes and 54% segmented cells), and the Rivalta test was negative. LDH and adenosine deaminase (ADA) levels were 381.00 U/L (0~247 U/L) and 15.00 U/L, respectively. There were no malignant cells in the pleural effusion. Considering the possibility of opportunistic pathogens, additional drugs were added to cover nocardia and pneumocystic infections. However, his temperature still increased to 40 °C. A second CT-guided biopsy was performed on 27th day to find the cause of repeated fever, and the pathological examination of the specimen revealed polygonal atypical lymphoid cell proliferation with necrosis. The second PAS staining and tissue culture were also negative. Immunohistochemical staining on 35th day showed positive markers for CD20, EBER, BCL-2, PAX5, MUM-1 and a Ki-67 rate of 70% (Fig. 2), which was consistent with a diagnosis of diffuse large B-cell lymphoma (DLBCL). He also had a serum IgM test for Epstein–Barr virus (EBV) and other viruses, including influenza and toxoplasma, rubella virus, cytomegalovirus, herpes virus (TORCH), which were all negative. The EBV load was less than 5*103 (< 5*103). He was therefore diagnosed with synchronous pulmonary aspergillosis and DLBCL. Despite the combined R-COPE chemotherapy (rituximab 600 mg d 0 + cyclophosphamide 0.4 g d1–2 + vindesine 4 mg d1 + dexamethasone 20 mg d1–4 + VP-16 0.1 g d1–2) starting 38th days after hospitalization, the patient’s situation continued to deteriorate. He developed cervical, axillary and inguinal lymph node enlargement, which were unremarkable on admission. His LDH increased to 1627 U/L. The following CT scan (Fig. 1, G-I) showed bilateral pleural effusion, atelectasis and consolidations of all right lung lobes with air bronchograms. Then, the patient died of progressive respiratory failure on the 52nd day.

Fig. 1
figure 1

Chest CT findings during hospitalization. a-c: A CT scan of the chest (on admission) showing multiple nodules (thick arrows) and thick-walled cavities (black triangle) in lung fields as well as enlarged mediastinal lymph nodes. d-f: Subsequent chest CT (23rd day) showing new emerging round opacities (thick arrows), expending lung abscess and cavities (black stars), bilateral pleural effusion (thin arrows). g-i: Subsequent chest CT (49th day) showing increased pleural effusion, atelectasis and consolidations on both sides with air bronchograms (white star)

Fig. 2
figure 2

Pathological staining and immunohistochemical results. a-b: Coagulative necrosis and polygonal atypical lymphoid cell proliferation. Immunohistochemical staining shows positive markers for EBER (c, 400×) and CD20 (d, 400×) with a Ki-67 rate of 70% (e, 400×)

Discussion and conclusion

Lymphoma represents a spectrum of malignant neoplasms arising from the lymphoid system with an incidence of approximately 8% of all malignancies. 25 to 40% of HL/NHL tumours arise at extranodal sites. The most common sites are the gastrointestinal tract, tonsils, skin and connective tissues. Lymphomas originating from the lung may account for 3.6% of cases [7,8,9]. Pulmonary lymphoma may represent primary or secondary involvement of the lungs. Primary pulmonary lymphoma (PPL) has been defined as a clonal lymphoid proliferation affecting one or both lungs (parenchyma and/or bronchi) in a patient with no clinical, pathological, or radiographic evidence of lymphoma elsewhere, either in the past or at present or for 3 months after presentation [10]. Secondary pulmonary lymphoma is more common than PPL. It refers to a secondary involvement of the lung from a known extrapulmonary lymphoma or dominant pulmonary lesion, with indolent primary extrapulmonary lesions observed within 3 months [11, 12]. Lymphoma of the lung is asymptomatic or have nonspecific respiratory symptoms, such as fever, cough, dyspnoea, chest pain, and haemoptysis. Radiological manifestations of lymphoma involving the lung are also variable. The vast majority of cases present as multiple nodules, consolidation, solitary masses or cavities with or without enlarged lymph nodes. A rare subtype of lymphoma can also present with diffuse ground-glass shadows or pleural effusion on a chest CT scan [13]. Therefore, the differential diagnosis includes TB, fungal infections, interstitial lung disease, neoplastic disease and metastatic spread from solid malignancies.

Opportunistic infection frequently develops in people with reduced immunity, such as individuals with advanced age, diabetes mellitus, HIV infection, or a history of drug abuse, organ transplantation or immunosuppresive therapy. The presentation of an opportunistic infection is related to host immunity and physiological conditions. The lung is the classical site of opportunistic infection. Disseminated infections caused by Mycobacterium tuberculosis and pathogenic fungi can also manifest as multifocal infiltration and lymph node masses in the image. Therefore, significant overlaps exist among opportunistic infections and lymphoma.

The patient we reported first presented with a high fever and multiple pulmonary cavities on a CT scan. Based on the findings of microbiology, the initial diagnosis was pulmonary aspergillosis, which was consistent with the imaging. However, neither antifungal therapy nor multiple rounds of antibiotic therapy were effective. The patient’s lung lesions showed rapid progression, and he developed superficial lymph node enlargement during hospitalization. A repeat biopsy of the same lesion confirmed malignant lymphoma.

The coexistence of lymphoma and opportunistic infection at the initial time of diagnosis is rare in the literature. We chose “lymphoma”, “Hodgkin’s lymphoma”, “opportunistic infection”, “fungal infection”, “tuberculosis” etc. as keywords and searched cases from 1960 to present in the PubMed database through different combinations of keywords.

Only a few publications have reported this condition (Table 1) [14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30] (see Table 1. Reported cases of synchronous opportunistic infection and lymphoma). In all 18 cases, both diseases coexisted at initial presentation, with 12 cases of concomitant TB, 2 cases of pulmonary Aspergillus infection, 2 cases of pulmonary cryptococcosis, 1 case of Legionella pneumophila pneumonia, and 1 case of pulmonary cytomegalovirus (CMV) infection (Table 2).

Table 1 Reported cases of synchronous opportunistic infection and lymphoma
Table 2 Analysis of information about synchronous opportunistic infection and lymphoma

This condition can happen to individuals of any age or either gender. And it seems to be more frequent in males, with a ratio of approximately 2 to 1. Only one (no. 14) of the patients had an explicit history of diabetes mellitus, and one patient had urothelial cancer (status postresection, no. 9), and the other patients had no immunocompromised statuses previously. The three most prevalent clinical presentations among such patients are fever (50.0%), cough (38.9%) and superficial lymph node enlargement (27.8%). Most chest images indicate mediastinal or hilar lymph node enlargement, solitary or multiple pulmonary nodules and cavitating lesions. Other presentations include consolidation and hydrothorax on thorax CT scans (Table 3) (see Table 3 Clinical presentations and imaging features of the chest).

Table 3 Clinical presentations and imaging features of the chest

During the diagnostic process, the persistent clinical symptoms and new lesions are the main reasons prompting clinicians to take another cause into consideration. The diagnostic approach almost always involves various types of invasive methods, such as superficial lymph node biopsy (61.1%), bronchoscopy or BAL (38.9%), bone marrow aspiration (38.9%), transbronchial biopsy (33.3%), needle aspiration biopsy of lung lesions (27.8%), surgical operations (22.2%), mediastinoscopy (11.1%) and thoracoscopy (11.1%) (Table 4) (see Table 4 Multiple biopsy methods involved in diagnostic processes). Eighty percent of patients undergo more than one biopsy in the same or different lesions during the diagnostic process because of negative pathology results or a lack of satisfactory biopsy specimens. In only two cases (no. 7, 13), the same tissue specimen revealed Mycobacterium tuberculosis infection coexisting with lymphoma. Three cases (no. 2, 3,17) were diagnosed only by postmortem analysis. The time from initial onset to definite diagnosis ranged from 3 days to 14 months (Table 5).

Table 4 Multiple biopsy methods involved in diagnostic processes
Table 5 The delayed time and prognosis of each case

The concurrence of lymphoma and TB is more common than concomitant fungal infection. The cellular immunodeficiency that usually accompanies lymphoma is believed to be a predisposing factor for opportunistic infection. But an aetiological role cannot be completely excluded. It has been reported that the risk of NHL is significantly increased in individuals with a history of TB, which is related to the DNA damage and apoptosis inhibition caused by M. tuberculosis [31,32,33]. It is not clear whether aspergillosis plays a similar role.

The concurrence of pulmonary lymphoma and opportunistic infection poses a management dilemma for physicians. A delayed diagnosis of either opportunistic infection or lymphoma usually occurs in this clinical scenario. The reasons can be summarized as follows: (1) Common symptoms and radiographic findings are shared by both disorders. When lymphoma and opportunistic infection exist simultaneously, it is difficult to judge whether the multifocal lesions and lymphadenopathy are lymphoma infiltrations or associated with infection. It makes the selection of the biopsy site challenging. (2) Tissue biopsy is the gold standard for the diagnosis and typing of lymphoma. While needle biopsy is inclusive, the majority of the tumour is constituted by reactive or inflammatory cells in varying compositions, especially HL. In HL, the neoplastic Hodgkin and Reed-Sternberg cells represent only a minority of the cellular infiltrate, with a frequency ranging from 0.1–10% [34]. Therefore, a single needle aspiration biopsy cannot ensure diagnostic yield.

The dilemma of lymphoma complicated with opportunistic infection is also reflected in treatment. Immediate application of chemotherapy may induce potential infection and aggravate the severity of the primary infection, especially for a particularly weak patient. Thus, it is necessary to identify whether evidence of infection exists in pathological specimens by specimen culture or special stains in addition to immunohistochemical staining. If anti-infectious treatments are given first, clinicians must notice that continuous antibiotic treatment for chronic infection may result in suppression of lymphoma and then create an illusion of clinical remission [27]. Therefore, when the treatment is less effective than expected or the clinical manifestations are not consistent with the infection, clinicians should look for other potential causes as soon as possible. If both diseases are treated at the same time, the risk of drug toxicity may be increased. So, choosing appropriate treatment timing is very important for these patients. Additional clinical data about the therapeutic plan for this condition should be collected to improve the prognosis.

In conclusion, simultaneous lymphoma and opportunistic infection in a primary presentation is a challenging condition. The diagnostic process should involve maintaining a high index of suspicion based upon an understanding of the clinical and imaging manifestations, of the therapeutic effect, and of the limitations of diagnostic methods. Different and various invasive diagnostic methods, including needle aspiration or excision biopsy of lymph nodes, CT-guided transthoracic needle aspiration, transbronchial biopsy and bone marrow puncture, should be performed to reach an early diagnosis.